SCYNEXIS and Hansoh Pharma Report the NMPA Acceptance of NDA for Ibrexafungerp to Treat Adult and Post-Menarchal Pediatric Females with Vulvovaginal Candidiasis
Shots:
- The NMPA has accepted an NDA for review of oral ibrexafungerp tablets for adult & post-menarchal pediatric females with VVC in the Chinese mainland. The application was based on the P-III studies results showed a significant superiority over PBO for the primary & secondary study EPs
- SCYNEXIS & Hansoh Pharma collaborated in Feb 2021 to develop & commercialize ibrexafungerp in the greater China region while Hansoh is responsible for the development, regulatory approval & commercialization of ibrexafungerp in Greater China
- Ibrexafungerp, is currently in late-stage investigation & development for multiple indications, incl. life-threatening fungal infections caused primarily by Candida and Aspergillus species in hospitalized patients
Ref: Globenewswire | Image: SCYNEXIS
Related News:- SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
